Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesine
Cognition Therapeutics' Type C Meeting With FDA To Take Place Oct. 20 For Planned Trial Of Zervimesine